Transgenic mice expressing human APP (751) containing the London (V717I) and Swedish (K670M/N671L) mutations treated with isotype-nonspecific ACAT inhibitors, CP-113,818 and CI-1011 showed a reduction of Aβ and amyloid plaque levels and an amelioration of cognitive deficits [152,153]. Here, ACAT1 is linked to Cognitive impairment.